The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder

Journal of Psychiatric Research

Volumn 56, Issue 1, 2014, Pages 72-81

  Han, Changsu ^a   Pae, Chi Un ^b,c   Wang, Sheng Min ^b   Lee, Soo Jung ^b   Patkar, Ashwin A ^c   Masand, Praksh S ^d   Serretti, Alssandro ^e  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Global Medical Education Inc   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atypical antipsychotics; Efficacy; Meta analysis; Posttraumatic stress disorder; Tolerability

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; PLACEBO; NEUROLEPTIC AGENT;

AROUSAL; AVOIDANCE BEHAVIOR; CLINICIAN ADMINISTERED PTSD SCALE; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; META ANALYSIS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEIGHT GAIN; COMPLICATION; STRESS DISORDERS, POST-TRAUMATIC;

ANTIPSYCHOTIC AGENTS; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84903779829     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.05.003     Document Type: Review

References (49)

1. Ahearn E.P., Juergens T., Cordes T., Becker T., Krahn D. Areview of atypical antipsychotic medications for posttraumatic stress disorder. Int Clin Psychopharmacol 2011, 26:193-200.
2. American Psychiatric Association Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder 2004.
3. Amital D., Fostick L., Polliack M.L., Segev S., Zohar J., Rubinow A., et al. Posttraumatic stress disorder, tenderness, and fibromyalgia syndrome: are they different entities?. JPsychosom Res 2006, 61:663-669.
4. Bajor L.A., Ticlea A.N., Osser D.N. The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on posttraumatic stress disorder. Harv Rev Psychiatry 2011, 19:240-258.
5. Baldwin D.S., Anderson I.M., Nutt D.J., Bandelow B., Bond A., Davidson J.R., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. JPsychopharmacol 2005, 19:567-596.
6. Bandelow B., Sher L., Bunevicius R., Hollander E., Kasper S., Zohar J., et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 2012, 16:77-84.
7. Bartzokis G., Lu P.H., Turner J., Mintz J., Saunders C.S. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005, 57:474-479.
8. Berry K., Ford S., Jellicoe-Jones L., Haddock G. PTSD symptoms associated with the experiences of psychosis and hospitalisation: a review of the literature. Clin Psychol Rev 2013, 33:526-538.
9. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Gusman F.D., Charney D.S., et al. The development of a Clinician-Administered PTSD Scale. JTrauma Stress 1995, 8:75-90.
10. Blomhoff S., Reinvang I., Malt U.F. Event-related potentials to stimuli with emotional impact in posttraumatic stress patients. Biol Psychiatry 1998, 44:1045-1053.
11. Bunting B.P., Ferry F.R., Murphy S.D., O'Neill S.M., Bolton D. Trauma associated with civil conflict and posttraumatic stress disorder: evidence from the Northern Ireland study of health and stress. JTrauma Stress 2013, 26:134-141.
12. Butterfield M.I., Becker M.E., Connor K.M., Sutherland S., Churchill L.E., Davidson J.R. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001, 16:197-203.
13. Canadian Psychiatric Association Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006, 51:9S-91S.
14. Carey P., Suliman S., Ganesan K., Seedat S., Stein D.J. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 2012, 27:386-391.
15. Chibnall J.T., Duckro P.N. Post-traumatic stress disorder in chronic post-traumatic headache patients. Headache 1994, 34:357-361.
16. Connor K.M., Hidalgo R.B., Crockett B., Malik M., Katz R.J., Davidson J.R. Predictors of treatment response in patients with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:337-345.
17. Davidson J.R., Book S.W., Colket J.T., Tupler L.A., Roth S., David D., et al. Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 1997, 27:153-160.
18. Davidson J.R., Tharwani H.M., Connor K.M. Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. Depress Anxiety 2002, 15:75-78.
19. Eisenman D.P., Gelberg L., Liu H., Shapiro M.F. Mental health and health-related quality of life among adult Latino primary care patients living in the United States with previous exposure to political violence. JAMA 2003, 290:627-634.
20. Hamner M.B., Canive J., Robert S., Calais L.A., Villarreal G., Durkalski V. Quetiapine monotherapy in chronic posttraumatic stress disorder: A randomized, double-blind, placebo-controlled trial 2009, American Psychiatric Association Annual Meeting.
21. Hamner M.B., Faldowski R.A., Ulmer H.G., Frueh B.C., Huber M.G., Arana G.W. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003, 18:1-8.
22. Han C., Wang S.M., Kato M., Lee S.J., Patkar A.A., Masand P.S., et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 2013, 13:851-870.
23. Huf W., Kalcher K., Pail G., Friedrich M.E., Filzmoser P., Kasper S. Meta-analysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry 2011, 12:188-200.
24. Ipser J.C., Stein D.J. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). Int J Neuropsychopharmacol 2012, 15:825-840.
25. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
26. Kellner M., Muhtz C., Wiedemann K. Primary add-on of ziprasidone in sertraline treatment of posttraumatic stress disorder: lessons from a stopped trial?. JClin Psychopharmacol 2010, 30:471-473.
27. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
28. Kessler R.C., Sonnega A., Bromet E., Hughes M., Nelson C.B. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995, 52:1048-1060.
29. Krystal J.H., Rosenheck R.A., Cramer J.A., Vessicchio J.C., Jones K.M., Vertrees J.E., et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 2011, 306:493-502.
30. Leserman J., Whetten K., Lowe K., Stangl D., Swartz M.S., Thielman N.M. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south. Psychosom Med 2005, 67:500-507.
31. Marshall R.D., Schneier F.R., Fallon B.A., Knight C.B., Abbate L.A., Goetz D., et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. JClin Psychopharmacol 1998, 18:10-18.
32. Martenyi F., Brown E.B., Zhang H., Prakash A. andKoke SC. Fluoxetine versus placebo in posttraumatic stress disorder. JClin Psychiatry 2002, 63:199-206.
33. Monnelly E.P., Ciraulo D.A., Knapp C., Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. JClin Psychopharmacol 2003, 23:193-196.
34. O'Toole B.I., Marshall R.P., Schureck R.J., Dobson M. Posttraumatic stress disorder and comorbidity in Australian Vietnam veterans: risk factors, chronicity and combat. Aust N. Z J Psychiatry 1998, 32:32-42.
35. Padala P.R., Madison J., Monnahan M., Marcil W., Price P., Ramaswamy S., et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006, 21:275-280.
36. Pae C.U., Forbes A., Patkar A.A. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011, 25:109-127.
37. Pae C.U., Lee S.J., Han C., Patkar A.A., Masand P.S. Atypical antipsychotics as a possible treatment option for irritable bowel syndrome. Expert Opin Investig Drugs 2013, 22:565-572.
38. Pae C.U., Lim H.K., Peindl K., Ajwani N., Serretti A., Patkar A.A., et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008, 23:1-8.
39. Pae C.U., Patkar A.A. Clinical issues in use of atypical antipsychotics for depressed patients. CNS Drugs 2013, 27(Suppl.1):39-45.
40. Pae C.U., Serretti A., Patkar A.A., Masand P.S. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008, 22:367-388.
41. Pae C.U., Sohi M.S., Seo H.J., Serretti A., Patkar A.A., Steffens D.C., et al. Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1165-1173.
42. Reich D.B., Winternitz S., Hennen J., Watts T., Stanculescu C. Apreliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. JClin Psychiatry 2004, 65:1601-1606.
43. Rothbaum B.O., Killeen T.K., Davidson J.R., Brady K.T., Connor K.M., Heekin M.H. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. JClin Psychiatry 2008, 69:520-525.
44. Roy-Byrne P., Smith W.R., Goldberg J., Afari N., Buchwald D. Post-traumatic stress disorder among patients with chronic pain and chronic fatigue. Psychol Med 2004, 34:363-368.
45. Sareen J., Cox B.J., Goodwin R.D., J G Asmundson G. Co-occurrence of posttraumatic stress disorder with positive psychotic symptoms in a nationally representative sample. JTrauma Stress 2005, 18:313-322.
46. Schaffer A., McIntosh D., Goldstein B.I., Rector N.A., McIntyre R.S., Beaulieu S., et al. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 2012, 24:6-22.
47. Shevlin M., Armour C., Murphy J., Houston J.E., Adamson G. Evidence for a psychotic posttraumatic stress disorder subtype based on the National Comorbidity Survey. Soc Psychiatry Psychiatr Epidemiol 2011, 46:1069-1078.
48. Stein M.B., Kline N.A., Matloff J.L. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002, 159:1777-1779.
49. Watts B.V., Schnurr P.P., Mayo L., Young-Xu Y., Weeks W.B., Friedman M.J. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. JClin Psychiatry 2013, 74:e541-e550.